 Eli Lilly has made its first big purchase of the year. The pharmaceutical giant agreed to buy biopharma company Morphic for $3.2 billion. In the deal, Lilly picks up experimental therapies for inflammatory bowel disease and other chronic illnesses. Morphic's stock is soaring 76% higher this morning.